Department of Pediatric Immunology, Centre for Molecular and Clinical Immunology (CMCI), Laboratory for Translational Medicine, University Medical Centre Utrecht, Lundlaan 6/P.O. Box 85090, 3584 EA/3508 AB Utrecht, The Netherlands.
Department of Pediatric Immunology, Centre for Molecular and Clinical Immunology (CMCI), Laboratory for Translational Medicine, University Medical Centre Utrecht, Lundlaan 6/P.O. Box 85090, 3584 EA/3508 AB Utrecht, The Netherlands.
Best Pract Res Clin Rheumatol. 2014 Apr;28(2):229-46. doi: 10.1016/j.berh.2014.05.002.
Despite the enormous progress in the treatment of juvenile idiopathic arthritis (JIA), innovations based on true bench-to-bedside research, performed in JIA patients, are still scarce. This chapter describes novel developments in which clinical innovations go hand in hand with basic discoveries. For the purpose of this review, we will mainly focus on developments in severe forms of JIA, most notably systemic JIA and polyarticular JIA. However, also in less severe forms of JIA, such as oligoarticular JIA, better insight will help to improve diagnosis and treatment. Facilitating the transition from bench to bedside will prove crucial for addressing the major challenges in JIA management. If successful, it will set new standards for a safe, targeted and personalized therapeutic approach for children with JIA.
尽管在治疗幼年特发性关节炎（JIA）方面取得了巨大进展，但基于真正的从实验室到临床的研究，针对 JIA 患者的创新仍然很少。本章描述了临床创新与基础发现齐头并进的新进展。 为了进行本综述，我们将主要关注 JIA 的严重形式的发展，尤其是全身型 JIA 和多关节型 JIA。 然而，在不太严重的 JIA 形式中，如少关节型 JIA，更好的认识将有助于改善诊断和治疗。 促进从实验室到临床的转变对于解决 JIA 管理中的主要挑战至关重要。 如果成功，它将为 JIA 患儿的安全、靶向和个性化治疗方法设定新标准。
